<span style="color: #222222;">Bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country. The National AEFI (Adverse Event Following Immunization) Committee said this in a report submitted to the Health Ministry. Alerts have been raised in some countries on post-vaccination "embolic and thrombotic events" particularly with AstraZeneca-Oxford vaccine which is Covishield in India. A decision was taken to conduct an urgent in-depth analysis of the adverse events in India following global concerns.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">The National AEFI committee noted that since the COVID-19 vaccination drive was initiated, more than 23 thousand adverse events were reported through the CO-WIN platform from 684 of the 753 districts of the country. Of these, only 700 cases were reported to be of severe nature.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">The AEFI Committee completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic events.</span><br />'' <br />'' <span style="color: #222222;">There were no potential thromboembolic events reported following administration of Covaxin vaccine.</span><br />''  <br />